Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA
Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells. It has been suggested that by expression of FasL, BCC cells may evade...
Gespeichert in:
Veröffentlicht in: | Gene therapy 2005-04, Vol.12 (8), p.678-684 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 684 |
---|---|
container_issue | 8 |
container_start_page | 678 |
container_title | Gene therapy |
container_volume | 12 |
creator | Ji, J Wernli, M Mielgo, A Buechner, S A Erb, P |
description | Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells. It has been suggested that by expression of FasL, BCC cells may evade the attack of Fas-positive immune effector cells allowing the tumor to expand. Thus, downregulation of FasL should prime BCC to the assault of immune effector cells. Recently, it has been shown that RNA interference is a highly successful approach to specifically silence a gene of interest in single cells and some animal models. However, RNAi in human tissues has not been shown so far. Here, we provide evidence that small interfering RNAs (siRNAs) efficiently transfect tumor tissue
ex vivo
and silence the gene of interest. We demonstrate that a specific siRNA efficiently downregulates FasL not only in FasL-positive indicator cells but also in surgically excised BCC tissue at both the protein and the mRNA level. The successful transfection of tumor tissues with siRNAs now allows to test the function of the molecule under study and opens up the investigation of other target genes in the tumor. |
doi_str_mv | 10.1038/sj.gt.3302453 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67712416</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182811916</galeid><sourcerecordid>A182811916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c578t-a35c006673289ba1dd1f383ab3b4cb03995499c56b1682a8bfc94b92ad426f8e3</originalsourceid><addsrcrecordid>eNqF0u9r1DAYB_AiijunL30rxbGBL3rmV9P05TE2HQyFTV-Hp2nay9GmZ54U9b835w7Ok4kUWkg_T5In-WbZa0qWlHD1HjfLPi45J0yU_Em2oKKSRSkke5otSC3roqJMnWQvEDeEEFEp9jw7oaWUhFK2yO6vAYvB9eDbvLfe5ugG643zfe583gDCkBs7pBeENDqNkEeHONv8u4vrHEdI_5yPNnQ27KruPq1eZs86GNC-2n9Ps6_XV18uPxa3nz_cXK5uC1NWKhbAS0OIlBVnqm6Ati3tuOLQ8EaYhvC6LkVdm1I2VCoGqulMLZqaQSuY7JTlp9nFw7zbMH2bLUY9OtxtFrydZtSySr0LKv8LaaWk5KxM8OwvuJnm4FMTmkkhJK9YRZN6-09FVUUEo-wwVQ-D1c53UwxgduvqFVVMUVr_3tnyEZWe1o7OTN526TqOC94dFSQT7Y_Yw4yob-7vju3FH3ZtYYhrnIY5usnjMSweoAkTYrCd3gY3QvipKdG7lGnc6D7qfcqSf7M_gLkZbXvQ-1glcL4HgAaGLkCKFB6cTBcqZHloH7e78NhwOMnHV_4FNwnkCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218704212</pqid></control><display><type>article</type><title>Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ji, J ; Wernli, M ; Mielgo, A ; Buechner, S A ; Erb, P</creator><creatorcontrib>Ji, J ; Wernli, M ; Mielgo, A ; Buechner, S A ; Erb, P</creatorcontrib><description>Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells. It has been suggested that by expression of FasL, BCC cells may evade the attack of Fas-positive immune effector cells allowing the tumor to expand. Thus, downregulation of FasL should prime BCC to the assault of immune effector cells. Recently, it has been shown that RNA interference is a highly successful approach to specifically silence a gene of interest in single cells and some animal models. However, RNAi in human tissues has not been shown so far. Here, we provide evidence that small interfering RNAs (siRNAs) efficiently transfect tumor tissue
ex vivo
and silence the gene of interest. We demonstrate that a specific siRNA efficiently downregulates FasL not only in FasL-positive indicator cells but also in surgically excised BCC tissue at both the protein and the mRNA level. The successful transfection of tumor tissues with siRNAs now allows to test the function of the molecule under study and opens up the investigation of other target genes in the tumor.</description><identifier>ISSN: 0969-7128</identifier><identifier>EISSN: 1476-5462</identifier><identifier>DOI: 10.1038/sj.gt.3302453</identifier><identifier>PMID: 15660112</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animal models ; Apoptosis ; Applied cell therapy and gene therapy ; Basal cell carcinoma ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Carcinoma, Basal Cell - immunology ; Carcinoma, Basal Cell - therapy ; Cell Biology ; Cell culture ; Cell Line, Tumor ; Dermatology ; Effector cells ; fas Receptor - analysis ; fas Receptor - genetics ; FasL protein ; Flow Cytometry ; Fundamental and applied biological sciences. Psychology ; Gene Expression ; Gene Silencing ; Gene Therapy ; Genetic Therapy - methods ; Green Fluorescent Proteins ; Health. Pharmaceutical industry ; Human Genetics ; Humans ; Immunohistochemistry - methods ; In Situ Hybridization - methods ; Industrial applications and implications. Economical aspects ; Ligands ; Medical sciences ; Microscopy, Confocal ; mRNA ; Nanotechnology ; research-article ; Reverse Transcriptase Polymerase Chain Reaction ; Rhodamines ; RNA, Small Interfering - administration & dosage ; RNA-mediated interference ; siRNA ; Skin cancer ; Transfection ; Transfection - methods ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Tumors of the skin and soft tissue. Premalignant lesions</subject><ispartof>Gene therapy, 2005-04, Vol.12 (8), p.678-684</ispartof><rights>Springer Nature Limited 2005</rights><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2005</rights><rights>Nature Publishing Group 2005.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c578t-a35c006673289ba1dd1f383ab3b4cb03995499c56b1682a8bfc94b92ad426f8e3</citedby><cites>FETCH-LOGICAL-c578t-a35c006673289ba1dd1f383ab3b4cb03995499c56b1682a8bfc94b92ad426f8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.gt.3302453$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.gt.3302453$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16682465$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15660112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ji, J</creatorcontrib><creatorcontrib>Wernli, M</creatorcontrib><creatorcontrib>Mielgo, A</creatorcontrib><creatorcontrib>Buechner, S A</creatorcontrib><creatorcontrib>Erb, P</creatorcontrib><title>Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA</title><title>Gene therapy</title><addtitle>Gene Ther</addtitle><addtitle>Gene Ther</addtitle><description>Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells. It has been suggested that by expression of FasL, BCC cells may evade the attack of Fas-positive immune effector cells allowing the tumor to expand. Thus, downregulation of FasL should prime BCC to the assault of immune effector cells. Recently, it has been shown that RNA interference is a highly successful approach to specifically silence a gene of interest in single cells and some animal models. However, RNAi in human tissues has not been shown so far. Here, we provide evidence that small interfering RNAs (siRNAs) efficiently transfect tumor tissue
ex vivo
and silence the gene of interest. We demonstrate that a specific siRNA efficiently downregulates FasL not only in FasL-positive indicator cells but also in surgically excised BCC tissue at both the protein and the mRNA level. The successful transfection of tumor tissues with siRNAs now allows to test the function of the molecule under study and opens up the investigation of other target genes in the tumor.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animal models</subject><subject>Apoptosis</subject><subject>Applied cell therapy and gene therapy</subject><subject>Basal cell carcinoma</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Carcinoma, Basal Cell - immunology</subject><subject>Carcinoma, Basal Cell - therapy</subject><subject>Cell Biology</subject><subject>Cell culture</subject><subject>Cell Line, Tumor</subject><subject>Dermatology</subject><subject>Effector cells</subject><subject>fas Receptor - analysis</subject><subject>fas Receptor - genetics</subject><subject>FasL protein</subject><subject>Flow Cytometry</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression</subject><subject>Gene Silencing</subject><subject>Gene Therapy</subject><subject>Genetic Therapy - methods</subject><subject>Green Fluorescent Proteins</subject><subject>Health. Pharmaceutical industry</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>In Situ Hybridization - methods</subject><subject>Industrial applications and implications. Economical aspects</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Microscopy, Confocal</subject><subject>mRNA</subject><subject>Nanotechnology</subject><subject>research-article</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Rhodamines</subject><subject>RNA, Small Interfering - administration & dosage</subject><subject>RNA-mediated interference</subject><subject>siRNA</subject><subject>Skin cancer</subject><subject>Transfection</subject><subject>Transfection - methods</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><issn>0969-7128</issn><issn>1476-5462</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0u9r1DAYB_AiijunL30rxbGBL3rmV9P05TE2HQyFTV-Hp2nay9GmZ54U9b835w7Ok4kUWkg_T5In-WbZa0qWlHD1HjfLPi45J0yU_Em2oKKSRSkke5otSC3roqJMnWQvEDeEEFEp9jw7oaWUhFK2yO6vAYvB9eDbvLfe5ugG643zfe583gDCkBs7pBeENDqNkEeHONv8u4vrHEdI_5yPNnQ27KruPq1eZs86GNC-2n9Ps6_XV18uPxa3nz_cXK5uC1NWKhbAS0OIlBVnqm6Ati3tuOLQ8EaYhvC6LkVdm1I2VCoGqulMLZqaQSuY7JTlp9nFw7zbMH2bLUY9OtxtFrydZtSySr0LKv8LaaWk5KxM8OwvuJnm4FMTmkkhJK9YRZN6-09FVUUEo-wwVQ-D1c53UwxgduvqFVVMUVr_3tnyEZWe1o7OTN526TqOC94dFSQT7Y_Yw4yob-7vju3FH3ZtYYhrnIY5usnjMSweoAkTYrCd3gY3QvipKdG7lGnc6D7qfcqSf7M_gLkZbXvQ-1glcL4HgAaGLkCKFB6cTBcqZHloH7e78NhwOMnHV_4FNwnkCw</recordid><startdate>20050401</startdate><enddate>20050401</enddate><creator>Ji, J</creator><creator>Wernli, M</creator><creator>Mielgo, A</creator><creator>Buechner, S A</creator><creator>Erb, P</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7QO</scope><scope>7X8</scope></search><sort><creationdate>20050401</creationdate><title>Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA</title><author>Ji, J ; Wernli, M ; Mielgo, A ; Buechner, S A ; Erb, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c578t-a35c006673289ba1dd1f383ab3b4cb03995499c56b1682a8bfc94b92ad426f8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animal models</topic><topic>Apoptosis</topic><topic>Applied cell therapy and gene therapy</topic><topic>Basal cell carcinoma</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Carcinoma, Basal Cell - immunology</topic><topic>Carcinoma, Basal Cell - therapy</topic><topic>Cell Biology</topic><topic>Cell culture</topic><topic>Cell Line, Tumor</topic><topic>Dermatology</topic><topic>Effector cells</topic><topic>fas Receptor - analysis</topic><topic>fas Receptor - genetics</topic><topic>FasL protein</topic><topic>Flow Cytometry</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression</topic><topic>Gene Silencing</topic><topic>Gene Therapy</topic><topic>Genetic Therapy - methods</topic><topic>Green Fluorescent Proteins</topic><topic>Health. Pharmaceutical industry</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>In Situ Hybridization - methods</topic><topic>Industrial applications and implications. Economical aspects</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Microscopy, Confocal</topic><topic>mRNA</topic><topic>Nanotechnology</topic><topic>research-article</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Rhodamines</topic><topic>RNA, Small Interfering - administration & dosage</topic><topic>RNA-mediated interference</topic><topic>siRNA</topic><topic>Skin cancer</topic><topic>Transfection</topic><topic>Transfection - methods</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ji, J</creatorcontrib><creatorcontrib>Wernli, M</creatorcontrib><creatorcontrib>Mielgo, A</creatorcontrib><creatorcontrib>Buechner, S A</creatorcontrib><creatorcontrib>Erb, P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ji, J</au><au>Wernli, M</au><au>Mielgo, A</au><au>Buechner, S A</au><au>Erb, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA</atitle><jtitle>Gene therapy</jtitle><stitle>Gene Ther</stitle><addtitle>Gene Ther</addtitle><date>2005-04-01</date><risdate>2005</risdate><volume>12</volume><issue>8</issue><spage>678</spage><epage>684</epage><pages>678-684</pages><issn>0969-7128</issn><eissn>1476-5462</eissn><abstract>Basal cell carcinoma (BCC) is the most frequent cancer in the Caucasian population. Cells of BCC strongly express Fas-ligand (FasL), a member of the tumor necrosis family, which induces apoptosis in Fas receptor-expressing cells. It has been suggested that by expression of FasL, BCC cells may evade the attack of Fas-positive immune effector cells allowing the tumor to expand. Thus, downregulation of FasL should prime BCC to the assault of immune effector cells. Recently, it has been shown that RNA interference is a highly successful approach to specifically silence a gene of interest in single cells and some animal models. However, RNAi in human tissues has not been shown so far. Here, we provide evidence that small interfering RNAs (siRNAs) efficiently transfect tumor tissue
ex vivo
and silence the gene of interest. We demonstrate that a specific siRNA efficiently downregulates FasL not only in FasL-positive indicator cells but also in surgically excised BCC tissue at both the protein and the mRNA level. The successful transfection of tumor tissues with siRNAs now allows to test the function of the molecule under study and opens up the investigation of other target genes in the tumor.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>15660112</pmid><doi>10.1038/sj.gt.3302453</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0969-7128 |
ispartof | Gene therapy, 2005-04, Vol.12 (8), p.678-684 |
issn | 0969-7128 1476-5462 |
language | eng |
recordid | cdi_proquest_miscellaneous_67712416 |
source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animal models Apoptosis Applied cell therapy and gene therapy Basal cell carcinoma Biological and medical sciences Biomedical and Life Sciences Biomedicine Biotechnology Carcinoma, Basal Cell - immunology Carcinoma, Basal Cell - therapy Cell Biology Cell culture Cell Line, Tumor Dermatology Effector cells fas Receptor - analysis fas Receptor - genetics FasL protein Flow Cytometry Fundamental and applied biological sciences. Psychology Gene Expression Gene Silencing Gene Therapy Genetic Therapy - methods Green Fluorescent Proteins Health. Pharmaceutical industry Human Genetics Humans Immunohistochemistry - methods In Situ Hybridization - methods Industrial applications and implications. Economical aspects Ligands Medical sciences Microscopy, Confocal mRNA Nanotechnology research-article Reverse Transcriptase Polymerase Chain Reaction Rhodamines RNA, Small Interfering - administration & dosage RNA-mediated interference siRNA Skin cancer Transfection Transfection - methods Transfusions. Complications. Transfusion reactions. Cell and gene therapy Tumors of the skin and soft tissue. Premalignant lesions |
title | Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T08%3A17%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fas-ligand%20gene%20silencing%20in%20basal%20cell%20carcinoma%20tissue%20with%20small%20interfering%20RNA&rft.jtitle=Gene%20therapy&rft.au=Ji,%20J&rft.date=2005-04-01&rft.volume=12&rft.issue=8&rft.spage=678&rft.epage=684&rft.pages=678-684&rft.issn=0969-7128&rft.eissn=1476-5462&rft_id=info:doi/10.1038/sj.gt.3302453&rft_dat=%3Cgale_proqu%3EA182811916%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218704212&rft_id=info:pmid/15660112&rft_galeid=A182811916&rfr_iscdi=true |